{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:36:04Z","timestamp":1791401764325,"version":"4.3.3"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Induction chemotherapy in fit de novo acute myeloid leukaemia (AML) patients has historically combined an anthracycline with standard\u2010dose cytarabine (\u20187\u2009+\u20093\u2019) despite complete response (CR) rates of 50%\u201370%. In May 2023, our institution adopted the utilization of cladribine, cytarabine, idarubicin and venetoclax (CLIA\u2010VEN) for intensive remission\u2013induction therapy. In this retrospective study, outcomes of newly diagnosed adult AML patients who were consecutively treated with CLIA\u2010VEN (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920; 2023\u20132025) were compared to a historical cohort that received 7\u2009+\u20093 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200942; 2016\u20132023). The median interquartile range [IQR] age was 54 [42\u201363] years, 54% were male and 58% had European LeukemiaNet (ELN) 2022 adverse\u2010risk disease. CLIA\u2010VEN was associated with a higher cumulative incidence of composite CR (CCR) (90% vs. 54.8%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002) and minimal residual disease (MRD)\u2010negative CCR (93.8% vs. 40.9%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) at 28\u2009days. Any grade\u2009\u2265\u20092 end\u2010organ toxicity (45% vs. 59.5%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.28) and early mortality (0% vs. 16.7%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.09) were not increased with CLIA\u2010VEN. Utilizing propensity score guided inverse probability treatment weighting to balance baseline demographics, receipt of CLIA\u2010VEN was associated with improved overall survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002). Acknowledging the limitations of a retrospective single\u2010centre study, our data suggest that CLIA\u2010VEN has higher efficacy without increasing toxicity and the potential to prolong survival compared to the current standard of care in de novo AML patients.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70253","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T01:35:22Z","timestamp":1762997722000},"page":"570-578","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Venetoclax combined with cladribine, idarubicin, cytarabine (\n                    <scp>CLIA<\/scp>\n                    \u2010\n                    <scp>VEN<\/scp>\n                    ) results in higher remission rates over conventional 7\u2009+\u20093 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia"],"prefix":"10.1111","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-1345","authenticated-orcid":false,"given":"Benjamin J.","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chao Family Comprehensive Cancer Center University of California Irvine Health  Orange California USA"},{"name":"Department of Clinical Pharmacy Practice, School of Pharmacy &amp; Pharmaceutical Sciences University of California  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-2490","authenticated-orcid":false,"given":"Shawn P.","family":"Griffin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chao Family Comprehensive Cancer Center University of California Irvine Health  Orange California USA"},{"name":"Department of Clinical Pharmacy Practice, School of Pharmacy &amp; Pharmaceutical Sciences University of California  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Doh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chao Family Comprehensive Cancer Center University of California Irvine Health  Orange California USA"},{"name":"Department of Clinical Pharmacy Practice, School of Pharmacy &amp; Pharmaceutical Sciences University of California  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Quach","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chao Family Comprehensive Cancer Center University of California Irvine Health  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chao Family Comprehensive Cancer Center University of California Irvine Health  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyatida","family":"Chumnumsiriwath","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Department of Medicine, Division of Hematology and Oncology, Chao Family Comprehensive Cancer Center University of California Irvine Health  Orange California USA"},{"name":"Department of Medicine, Division of Hematology, Faculty of Medicine Naresuan Hospital Naresuan University  Phitsanulok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Department of Medicine, Division of Hematology and Oncology, Chao Family Comprehensive Cancer Center University of California Irvine Health  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ramos\u2010Perez","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Department of Medicine, Division of Hematology and Oncology, Chao Family Comprehensive Cancer Center University of California Irvine Health  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Bellman","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Department of Medicine, Division of Hematology and Oncology, Chao Family Comprehensive Cancer Center University of California Irvine Health  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jeyakumar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Chao Family Comprehensive Cancer Center University of California Irvine Health  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyanuch","family":"Kongtim","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Department of Medicine, Division of Hematology and Oncology, Chao Family Comprehensive Cancer Center University of California Irvine Health  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Naqvi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Chao Family Comprehensive Cancer Center University of California Irvine Health  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"4","key":"e_1_2_12_2_1","first-page":"485","article-title":"Cytosine arabinoside (NSC\u201063878) and daunorubicin (NSC\u201083142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates JW","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904544"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.05.011"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.116"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1639.1639"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010276"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26601"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00192-7"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00106-5"},{"key":"e_1_2_12_12_1","volume-title":"Venclexta [package insert]","year":"2024"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0920-z"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01287-9"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215239"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1464158"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01066-y"},{"key":"e_1_2_12_19_1","unstructured":"National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.2020.https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 15 July 2024"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.23"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4874"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106318"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107346"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209476"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204627"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.1286"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142092"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001728"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1361028"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.09.005"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.10.025"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003988"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70253","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T18:26:52Z","timestamp":1772994412000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/bjh.70253"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70253","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"2025-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}